Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2022 / Mar / A Light in the Darkness
Oncology Analytical science Liquid biopsy Oncology Precision medicine Opinion and Personal Narratives

A Light in the Darkness

Spectroscopic liquid biopsy testing – a new route to brain cancer diagnostics

By Matthew J. Baker, Paul Brennan 03/04/2022 Opinion 2 min read

Share

Fast and effective routes to cancer diagnosis have never been more needed. Thanks to COVID-19, hospitals are burdened by a huge backlog of routine procedures. The scale of the impact of the pandemic on hospital care, and in particular on cancer treatment, is now becoming increasingly apparent.

We need innovative strategies to stratify patients’ risk of cancer and to prioritize patients for diagnostic investigations – and here’s where technologies incorporating high-level artificial intelligence (AI) could play a key role. AI applications in healthcare have progressed rapidly in the past few years and new, innovative ways of implementing AI are starting to make a real difference within diagnostics. These methods are already being used across the world; for example, AI now assists with detecting lung cancer – one of the most common cancers – from CT scans (1).

AI applications also have an important role in supporting the diagnosis of rare cancers, such as brain cancers – a traditionally difficult task. Patients most often present to primary care with nonspecific symptoms indicative of more probable non-cancer diagnoses. Referring every patient for expensive brain scans is neither possible nor cost effective. The best-performing symptom-based referral guidelines for suspected brain tumor only expect to identify a brain tumor approximately 3 percent of the time (2), so developing translatable technology that can be implemented within the clinic to improve triage for brain imaging is a major unmet need. Because smaller tumors are more often and more easily managed surgically, with less harm to the patient, early cancer detection is a key goal for improving patient outcomes.

Spectroscopic liquid biopsy is an innovative strategy for assessing blood samples – and, because it is quick and cost-effective, it could be a major game-changer in the diagnosis of cancer and other diseases. Blood samples are readily available and convenient for patients, so can be ordered earlier than current diagnostic pathways in the investigation of new-onset nonspecific symptoms. The low-cost technology, based on the interaction of infrared light with molecules present in the patient sample, generates a biological signal which can then be classified using an AI algorithm to detect cancer. In the brain tumor population, this allows the detection of disease within a symptomatic population – identifying which patients need urgent imaging and which do not.

Advances in AI have allowed us to maximize the opportunity that computational approaches offer for the detection of cancer and other diseases. If the technology is harnessed appropriately, spectroscopy-based liquid biopsy and AI have the potential to not just triage patients effectively, but ultimately increase survival rates and improve quality of life.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. E Svoboda, “Artificial intelligence is improving the detection of lung cancer,” Nature, 587, S20 (2020). PMID: 33208974.
  2. K Zienius et al., “Direct access CT for suspicion of brain tumour: an analysis of referral pathways in a population-based patient group,” BMC Fam Pract, 20, 118 (2019). PMID: 31431191.

About the Author(s)

Matthew J. Baker

More Articles by Matthew J. Baker

Paul Brennan

More Articles by Paul Brennan

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Opening a Window into Brain Trauma
Analytical science
Opening a Window into Brain Trauma

January 18, 2024

4 min read

Raman spectroscopy shows promise as the first point-of-care diagnostic device for TBI

Could ≠ Should
Analytical science
Could ≠ Should

January 20, 2022

1 min read

The need to prevent the ordering of unnecessary tests

Diamonds Are a Diagnostician’s Best Friend
Analytical science
Diamonds Are a Diagnostician’s Best Friend

February 8, 2022

1 min read

A diagnostic sensor for rapid, cost-effective, and accurate detection of SARS-CoV-2

Hunting the Unknown
Analytical science
Hunting the Unknown

February 22, 2022

1 min read

When it comes to human health, we cannot ignore unknown molecules simply because they present analytical challenges

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.